default author photo

Purnima Sravanti Teegavarapu

Baylor College of Medicine

One Baylor Plaza

Apt 510

Houston, TX TX - Texas 77030

United States

SCHOLARLY PAPERS

2

DOWNLOADS

59

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Chemorefractory Diffuse Large B-Cell Lymphoma- is a Cure Possible with Bruton Tyrosine Kinase Inhibitor?

Number of pages: 16 Posted: 03 Dec 2021
Purnima Sravanti Teegavarapu, Monira Haque, Andreia Barbieri, Gustavo Rivero and Martha Mims
Baylor College of Medicine, Baylor College of Medicine, Baylor College of Medicine, Baylor College of Medicine and Baylor University - Department of Medicine
Downloads 32 (1,290,922)

Abstract:

Loading...

Chemorefractory, Diffuse Large B-cell Lymphoma (DLBCL), Bruton Tyrosine Kinase Inhibitor (BTK), Ibrutinib, Activated B-cell (ABC), Germinal Center B-cell (GCB), B-cell receptor (BCR)

2.

Clinical Outcomes and Patterns of Care Among Patients with Newly Diagnosed Hodgkin Lymphoma in a Safety-Net Health System

Number of pages: 21 Posted: 04 Jun 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, Baylor College of Medicine, affiliation not provided to SSRN, Baylor University - Section of Epidemiology and Population Sciences, Baylor University - Section of Epidemiology and Population Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Baylor College of Medicine, affiliation not provided to SSRN, University of Texas at Houston - Department of Lymphoma and Myeloma, Baylor University - Section of Hematology-Oncology and affiliation not provided to SSRN
Downloads 27 (1,359,097)

Abstract:

Loading...

Hodgkin lymphoma, health disparity, outcomes research